CSIMarket
 
Bionano Genomics Inc   (BNGO)
Other Ticker:  
 
 
Price: $0.8299 $-0.01 -1.671%
Day's High: $0.8499 Week Perf: -1.71 %
Day's Low: $ 0.82 30 Day Perf: -27.83 %
Volume (M): 608 52 Wk High: $ 4.85
Volume (M$): $ 505 52 Wk Avg: $1.55
Open: $0.83 52 Wk Low: $0.47



 Market Capitalization (Millions $) 44
 Shares Outstanding (Millions) 53
 Employees -
 Revenues (TTM) (Millions $) 34
 Net Income (TTM) (Millions $) -220
 Cash Flow (TTM) (Millions $) 27
 Capital Exp. (TTM) (Millions $) 0

Bionano Genomics Inc
Bionano Genomics Inc is a biotechnology company based in San Diego, California. The company specializes in developing and commercializing cutting-edge genome analysis systems and tools. Bionano Genomics' flagship product is the Saphyr system, which is used for high-resolution structural variation detection and genome mapping. This system provides researchers and clinicians with a comprehensive view of genomes at unrivaled scale and resolution. Bionano Genomics' technology has applications in various fields such as clinical research, cancer genomics, and prenatal genetic testing. The company aims to revolutionize genomics research and advance precision medicine through its innovative solutions.


   Company Address: 9540 Towne Centre Drive, Suite 100 San Diego 92121 CA
   Company Phone Number: 888-7600   Stock Exchange / Ticker: NASDAQ BNGO
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Spotlight on Genomics: Leukemia's Hidden Genetic Variations Deciphered through Groundbreaking Techniques

Published Wed, Apr 24 2024 12:01 PM UTC

In a significant breakthrough in cancer research, Bionano Genomics Inc. has publicized the results of a study showcasing the efficacy of Optical Genome Mapping (OGM) in the detection of high-resolution structural variations in leukemia samples. These findings were subsequently substantiated using Cas9-Directed Nanopore Sequencing ?? an advanced technique that epitomizes the ...

Partnership

A Pioneering Venture: Bionano and Diagens Collaborate to Elevate Cytogenetic Analysis with Integrated OGM and AI

Published Wed, Apr 17 2024 12:01 PM UTC

In a revolutionary partnership that could potentially redefine cytogenetic analysis for reproductive health in China, two major players in the biotechnology world, Bionano and Diagens, have announced plans to commercialize the first-ever clinical cytogenetic analysis integrating optical genome mapping (OGM) and artificial intelligence (AI).Bionano Genomics is a prominent lif...

Clinical Study

Optical Genome Mapping Enhances Detection of Structural Variants in Pediatric Leukemia

Published Thu, Apr 11 2024 12:00 PM UTC

Genomic analysis plays a crucial role in understanding various diseases, particularly in pediatric oncology. Recent studies have highlighted the limitations of conventional techniques such as whole genome sequencing (WGS) in accurately detecting structural variants (SVs). However, a breakthrough publication by Bionano Genomics presents a compelling case for the utilization o...

Clinical Study

Bionano's Optical Genome Mapping (OGM) Bolsters Sarcoma Diagnosis: Study Uncovers Elusive Genetic Aberrations, Paving the Way for Enhanced Personalized Medicine

Published Wed, Apr 3 2024 12:00 PM UTC

In a bid to improve the diagnosis and understanding of solid tumor cancers, scientific researchers have reaffirmed the remarkable potential of optical genome mapping (OGM) to identify genetic aberrations that were previously missed by classical cytogenetic techniques. Bionano Genomics, an innovative life sciences company, recently published the results of a peer-reviewed stu...

Clinical Study

In a recent study published in the esteemed journal Oncology, Bionano Genomics, Inc. presented groundbreaking findings on the application of optical genome mapping (OGM) in hereditary breast and ovarian cancer (HBOC) syndrome. The study revealed that tumors with higher overall numbers of structural variations (SVs) exhibited an increased prevalence of mutated genes and altered signaling pathwa...

Published Tue, Mar 19 2024 12:00 PM UTC

Advancements in Optical Genome Mapping Provide Novel Insights into Prognosis, Tumor Progression, and Chemotherapy Resistance in Hereditary Breast and Ovarian Cancer SyndromeIn a recent study published in the esteemed journal Oncology, Bionano Genomics, Inc. presented groundbreaking findings on the application of optical genome mapping (OGM) in hereditary breast and ovarian c...






 

Bionano Genomics Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com